 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
CLINICAL SCIENCE |
*Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy; Department of Nephrology, G. Brotzu Hospital, Cagliari, Italy; and Department of Nephrology, IRCCS, Maggiore Hospital, Milan, Italy
Correspondence to Prof. Dr. Claudio Pozzi, Department of Nephrology and Dialysis, Ospedale Alessandro Manzoni, Via dell’Eremo 9, 23900 Lecco, Italy. Phone: +39-0341-489861; Fax: +39-0341-489860;
ABSTRACT. Proteinuria plays a causal role in the progression of IgA nephropathy (IgAN). A previous controlled trial showed that steroids are effective in reducing proteinuria and preserving renal function in patients with IgAN. The objective of this study was to evaluate the long-term effectiveness of steroids in IgAN, examine the trend of proteinuria during follow-up (starting from the hypothesis that the degree of reduction in proteinuria may influence IgAN outcome), and evaluate how histologic scores can influence steroid response. A secondary analysis of a multicenter, randomized, controlled trial of 86 adult IgAN patients who were receiving supportive therapy or intravenous methylprednisolone plus oral prednisone for 6 mo was conducted. Ten-year renal survival was significantly better in the steroid than in the control group (97% versus 53%; log rank test P = 0.0003). In the 72 patients who did not reach the end point (doubling in baseline serum creatinine), median proteinuria significantly decreased (1.9 g/24 h at baseline, 1.1 g/24 h after 6 mo, and 0.6 g/24 h after a median of 7 yr). In the 14 progressive patients, proteinuria increased from a median of 1.7 g/24 h at baseline to 2.0 g/24 h after 6 mo and 3.3 g/24 h after a median of 5 yr. Steroids were effective in every histologic class. Cox multivariate regression analyses showed that, in addition to steroids, a low baseline histologic score, a reduction in proteinuria after 6 mo, and no increase in proteinuria during follow-up all were independent predictors of a beneficial outcome. Steroids significantly reduce proteinuria and protect against renal function deterioration in IgAN. The histologic picture and proteinuria during early and late follow-up improve the prediction of outcome, but considerable variability remains outside the model. E-mail: c.pozzi@ospedale.lecco.it
This article has been cited by other articles:
 |
|
 |
|
  R. Katafuchi, T. Ninomiya, T. Mizumasa, K. Ikeda, H. Kumagai, M. Nagata, and H. Hirakata The improvement of renal survival with steroid pulse therapy in IgA nephropathy Nephrol. Dial. Transplant., December 1, 2008; 23(12): 3915 - 3920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Harada, Y. Akai, Y. Yamaguchi, K. Kimura, Y. Nishitani, K. Nakatani, M. Iwano, and Y. Saito Prediction of corticosteroid responsiveness based on fibroblast-specific protein 1 (FSP1) in patients with IgA nephropathy Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3152 - 3159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Komatsu, S. Fujimoto, S. Hara, Y. Sato, K. Yamada, and K. Kitamura Effect of Tonsillectomy Plus Steroid Pulse Therapy on Clinical Remission of IgA Nephropathy: A Controlled Study Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1301 - 1307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. GLASSOCK IgA nephropathy: Challenges and opportunities Cleveland Clinic Journal of Medicine, August 1, 2008; 75(8): 569 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Imai, K. Yamagata, K. Iseki, H. Iso, M. Horio, H. Mkino, A. Hishida, and S. Matsuo Kidney Disease Screening Program in Japan: History, Outcome, and Perspectives Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1360 - 1366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. W. Ballardie Quantitative Appraisal of Treatment Options for IgA Nephropathy J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2806 - 2809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Tumlin, M. P. Madaio, and R. Hennigar Idiopathic IgA Nephropathy: Pathogenesis, Histopathology, and Therapeutic Options Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 1054 - 1061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kikuchi, T. Imakiire, M. Yamada, T. Saigusa, T. Hyodo, T. Kushiyama, K. Higashi, N. Hyodo, K. Yamamoto, S. Suzuki, et al. Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1593 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Locatelli, C. Pozzi, and S. Andrulli Reply Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1785 - 1785. [Full Text] [PDF]
|
|
|
|
|
|
R. Coppo, L. Peruzzi, A. Amore, A. Piccoli, P. Cochat, R. Stone, M. Kirschstein, T. Linne, and on behalf of the EC Biomed Concerted Action Projec IgACE: A Placebo-Controlled, Randomized Trial of Angiotensin-Converting Enzyme Inhibitors in Children and Young People with IgA Nephropathy and Moderate Proteinuria J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1880 - 1888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Leung, A. Dispenzieri, M. Q. Lacy, S. K. Kumar, S. R. Hayman, F. C. Fervenza, S. S. Cha, and M. A. Gertz Severity of Baseline Proteinuria Predicts Renal Response in Immunoglobulin Light Chain-Associated Amyloidosis after Autologous Stem Cell Transplantation Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 440 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Uchida, Y. Nakamura, M. Kaihara, H. Norii, Y. Hanayama, H. Sugiyama, Y. Maeshima, Y. Yamasaki, and H. Makino Steroid pulse therapy impaired endothelial function while increasing plasma high molecule adiponectin concentration in patients with IgA nephropathy Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3475 - 3480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Locatelli, C. Pozzi, and S. Andrulli IgA nephritis: ACE inhibitors, steroids, both or neither? Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3357 - 3361. [Full Text] [PDF]
|
|
|
|
|
|
G. B. Appel To Treat or Not to Treat IgA Nephropathy? That Is the Question! Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 347 - 348. [Full Text] [PDF]
|
|
|
|
|
|
N. Yoshikawa, M. Honda, K. Iijima, M. Awazu, S. Hattori, K. Nakanishi, H. Ito, and for the Japanese Pediatric IgA Nephropathy Treatme Steroid Treatment for Severe Childhood IgA Nephropathy: A Randomized, Controlled Trial Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 511 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Hogg, J. Lee, N. Nardelli, B. A. Julian, D. Cattran, B. Waldo, R. Wyatt, J. C. Jennette, R. Sibley, K. Hyland, et al. Clinical Trial to Evaluate Omega-3 Fatty Acids and Alternate Day Prednisone in Patients with IgA Nephropathy: Report from the Southwest Pediatric Nephrology Study Group Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 467 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Tuffin, E. Waelti, J. Huwyler, C. Hammer, and H.-P. Marti Immunoliposome Targeting to Mesangial Cells: A Promising Strategy for Specific Drug Delivery to the Kidney J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3295 - 3305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Nagy, T. Kovacs, and I. Wittmann Renal protection in IgA nephropathy requires strict blood pressure control Nephrol. Dial. Transplant., August 1, 2005; 20(8): 1533 - 1539. [Full Text] [PDF]
|
|
|
|
|
|
J. Barratt and J. Feehally IgA Nephropathy J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2088 - 2097. [Full Text] [PDF]
|
|
|
|
|
|
M. Laville and E. Alamartine Treatment options for IgA nephropathy in adults: a proposal for evidence-based strategy Nephrol. Dial. Transplant., August 1, 2004; 19(8): 1947 - 1951. [Full Text] [PDF]
|
|
|
|
|
|
F. W. Ballardie IgA nephropathy treatment 25 years on: can we halt progression? The evidence base Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1041 - 1046. [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
